Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics

References

• Amsterdam, V., A. O. Jan, and W. van den Brink. 2011. Harm potential of magic mushroom use: A review. Regulatory Toxicology and Pharmacology 59 (3):423–29. doi:10.1016/j.yrtph.2011.01.006.
   PubMed Web of Science ®Google Scholar
• Andreia Machado, B.D.C., D. Dias-da-Silva, N. G. Gomes, R. J. Dinis-Oliveira, and Á. Madureira-Carvalho. 2020. Toxicokinetics and toxicodynamics of ayahuasca alkaloids N, N-dimethyltryptamine (DMT), harmine, harmaline and tetrahydroharmine: Clinical and forensic impact. Pharmaceuticals 13 (11):334. doi:10.3390/ph13110334.
   Web of Science ®Google Scholar
• Barsuglia, J., A. K. Davis, R. Palmer, R. Lancelotta, A.M. Windham-Herman, K. Peterson, M. Polanco, R. Grant, and R. R. Griffiths. 2018. Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison with a prior psilocybin study. Frontiers in Psychology 9:2459. doi:10.3389/fpsyg.2018.02459.
   PubMed Web of Science ®Google Scholar
• Bender, D., and D. J. Hellerstein. 2022. Assessing the risk–benefit profile of classical psychedelics: A clinical review of second-wave psychedelic research. Psychopharmacology 239 (6):1–26. doi:10.1007/s00213-021-06049-6.
   Web of Science ®Google Scholar
• Beug, M. W., and J. Bigwood. 1982. Psilocybin and psilocin levels in twenty species from seven genera of wild mushrooms in the Pacific Northwest, USA. Journal of Ethnopharmacology 5 (3):271–85. doi:10.1016/0378-8741(82)90013-7.
   PubMed Web of Science ®Google Scholar
• Bigwood, J., and M. W. Beug. 1982. Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (Earle) Singer. Journal of Ethnopharmacology 5 (3):287–91. doi:10.1016/0378-8741(82)90014-9.
   PubMed Web of Science ®Google Scholar
• Bogenschutz, M. P., A. A. Forcehimes, J. A. Pommy, C. E. Wilcox, P. C. R. Barbosa, and R. J. Strassman. 2015. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology 29 (3):289–99. doi:10.1177/0269881114565144.
   PubMed Web of Science ®Google Scholar
• California, L. 2021. SB-519 Controlled substances: Decriminalization of certain hallucinogenic substances. https://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=202120220SB519.
   Google Scholar
• California, L. 2023. SB-58 Controlled substances: Decriminalization of certain hallucinogenic substances. https://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=202320240SB58
   Google Scholar
• Dinis-Oliveira, R. J. 2017. Metabolism of psilocybin and psilocin: Clinical and forensic toxicological relevance. Drug Metabolism Reviews 49 (1):84–91. doi:10.1080/03602532.2016.1278228.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira, R. J., C. Lança Pereira, and D. D. da Silva. 2019. Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: Clinical and forensic repercussions. Current Molecular Pharmacology 12 (3):184. doi:10.2174/1874467211666181010154139.
   PubMed Web of Science ®Google Scholar
• Doblin, R. 1991. Pahnke’s “Good Friday experiment”: A long-term follow-up and methodological critique. The Journal of Transpersonal Psychology 23 (1):1–28.
   Google Scholar
• Dowell, D., T. M. Haegerich, and R. Chou. 2016. CDC guideline for prescribing opioids for chronic pain—United States, 2016. Jama 315 (15):1624–45. doi:10.1001/jama.2016.1464.
   PubMed Web of Science ®Google Scholar
• EMCDDA, (European Monitoring Centre for Drugs and Drug Addiction). 2016. Recent changes in Europe’s MDMA/ecstasy market. EMCDDA Rapid Communication. doi:10.2810/817237.
   Google Scholar
• Erowid. 1999. “5-Meo-DMT dosage.” Accessed 23 July 2022. https://erowid.org/chemicals/5meo_dmt/5meo_dmt_dose.shtml.
   Google Scholar
• Feuer, W. 2020. Oregon becomes first state to legalize magic mushrooms as more states ease drug laws in ‘psychedelic renaissance’. CNBC.com.
   Google Scholar
• Garcia-Romeu, A., F. S. Barrett, T. M. Carbonaro, M. W. Johnson, and R. R. Griffiths. 2021. Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. Journal of Psychopharmacology 35 (4):0269881121991822. doi:10.1177/0269881121991822.
   Web of Science ®Google Scholar
• Garcia-Romeu, A., B. Kersgaard, and P. H. Addy. 2016. Clinical applications of hallucinogens: A review. Experimental and Clinical Psychopharmacology 24 (4):229. doi:10.1037/pha0000084.
   PubMed Web of Science ®Google Scholar
• Gartz, J. 1994. Extraction and analysis of indole derivatives from fungal biomass. Journal of Basic Microbiology 34 (1):17–22. doi:10.1002/jobm.3620340104.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., M. W. Johnson, W. A. Richards, B. D. Richards, R. Jesse, K. A. MacLean, F. S. Barrett, M. P. Cosimano, and M. A. Klinedinst. 2018. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology 32 (1):49–69. doi:10.1177/0269881117731279.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., M. W. Johnson, W. A. Richards, B. D. Richards, U. McCann, and R. Jesse. 2011. Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology 218:649–65. doi:10.1007/s00213-011-2358-5.
   PubMed Web of Science ®Google Scholar
• Holze, F., L. Ley, F. Müller, A. M. Becker, I. Straumann, P. Vizeli, S. Silva Kuehne, M. A. Roder, U. Duthaler, K. E. Kolaczynska, et al. 2022. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology 47 (6):1180–87. doi:10.1038/s41386-022-01297-2.
   PubMed Web of Science ®Google Scholar
• Jerome, L., A. A. Feduccia, J. B. Wang, S. Hamilton, B. Klosinski, A. Emerson, M. C. Mithoefer, and R. Doblin. 2020. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: A longitudinal pooled analysis of six phase 2 trials. Psychopharmacology 237 (8):2485–97. doi:10.1007/s00213-020-05548-2.
   PubMed Web of Science ®Google Scholar
• Köck, P., K. Frölich, M. Walter, U. Lang, and K. M. Dürsteler. 2021. A systematic literature review of clinical trials and therapeutic applications of ibogaine. Journal of Substance Abuse Treatment 108717:108717. doi:10.1016/j.jsat.2021.108717.
   Web of Science ®Google Scholar
• Leonard, J. B., B. Anderson, and W. Klein-Schwartz. 2018. Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016. Journal of Psychopharmacology 32 (12):1286–94. doi:10.1177/0269881118793086.
   PubMed Web of Science ®Google Scholar
• Liechti, M. E., and F. Holze. 2021. Dosing Psychedelics and MDMA. In Disruptive psychopharmacology. current topics in behavioral neurosciences, ed. F. S. Barrett and K. H. Preller, Vol. 56, 3–21. Cham: Springer.
   Google Scholar
• Mitchell, J. M., M. Bogenschutz, A. Lilienstein, C. Harrison, S. Kleiman, K. Parker-Guilbert, G. Marcela Ot’alora, W. Garas, C. Paleos, I. Gorman, et al. 2021. MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine 27 (6):1025–33. doi:10.1038/s41591-021-01336-3.
   PubMed Web of Science ®Google Scholar
• Papaseit, E., C. Pérez-Mañá, M. Torrens, A. Farré, L. Poyatos, O. Hladun, A. Sanvisens, R. Muga, and M. Farré. 2020. MDMA interactions with pharmaceuticals and drugs of abuse. Expert Opinion on Drug Metabolism & Toxicology 16 (5):357–69. doi:10.1080/17425255.2020.1749262.
   PubMed Web of Science ®Google Scholar
• Ravani, S. 2019. Oakland decriminalizes shrooms and other natural psychedelics. San Francisco Chronicle 56 621. Accessed //2019. https://www.sfchronicle.com/bayarea/article/Oakland-expected-to-vote-tonight-on-whether-to-13937792.php.
   Google Scholar
• Reiff, C. M., E. E. Richman, C. B. Nemeroff, L. L. Carpenter, A. S. Widge, C. I. Rodriguez, N. H. Kalin, and W. M. McDonald. 2020. Work group on biomarkers, and a division of the American psychiatric association council of research novel treatments. The American Journal of Psychiatry 177 (5):391–410. doi:10.1176/appi.ajp.2019.19010035.
   PubMed Web of Science ®Google Scholar
• Uthaug, M. V., R. Lancelotta, A. M. Ortiz Bernal, A. K. Davis, and J. G. Ramaekers. 2020. A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting. Journal of Psychedelic Studies 4 (2):104–13. doi:10.1556/2054.2020.00123.
   Google Scholar
• Vizeli, P., and M. E. Liechti. 2017. Safety pharmacology of acute MDMA administration in healthy subjects. Journal of Psychopharmacology 31 (5):576–88. doi:10.1177/0269881117691569.
   PubMed Web of Science ®Google Scholar
• Webster, P. 2019. Denver votes to decriminalise psilocybin mushrooms. The Lancet 393 (10185):2023. doi:10.1016/S0140-6736(19)31082-7.
   PubMed Web of Science ®Google Scholar